MedTrace Logo

The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders

NCT01183221 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-04-15

Study results available
· View outcomes & findings →

Summary

This study examines the effects of a single dose of intranasal oxytocin (vs. placebo) on complex social cognition in adults with autism spectrum disorders.

Conditions

Interventions

DRUG

Syntocinon

One dose of 24 IU (3 sprays/nostril)

DRUG

Placebo

Intranasal Placebo

Sponsors & Collaborators

  • Alexander Kolevzon

    lead OTHER

Principal Investigators

  • Jennifer Bartz, P.h.D. · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-18
Primary Completion
2014-04-25
Completion
2014-04-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01183221 on ClinicalTrials.gov